Sun Pharma announced an all-cash acquisition of Organon for $11.75 billion as it expands its portfolio in women’s health and biosimilars. The deal, structured at $14 per share, brings Organon’s assets under Sun Pharma’s umbrella and signals continued consolidation in branded specialty and off-patent categories. For biotech and pharma investors, the transaction highlights how large platforms are using acquisitions to add commercial reach while leveraging manufacturing and lifecycle management capabilities. It also strengthens Sun’s position in therapeutic areas where biosimilar competition and product mix are key drivers.